| Tue 14 Dec 2010, 15:26 | | CMP - Cipla Medpro South Africa Limited - 2010 Antiretroviral tender results |
|
CMP
CMP
CMP - Cipla Medpro South Africa Limited - 2010 Antiretroviral tender results
CIPLA MEDPRO SOUTH AFRICA LIMITED
(Incorporated in the Republic of South Africa)
(Registration number 2002/018027/06)
(ISIN Number: ZAE000128179 Share Code: CMP)
("Cipla Medpro" or "the Group")
2010 ANTIRETROVIRAL TENDER RESULTS
Cipla Medpro is pleased to announce the results of the Antiretroviral (ARV)
Tender as released by the South African National Treasury Department yesterday
afternoon. The Group has been successful in securing meaningful volumes on some
key products. The tender is effective from 1 January 2011 to 31 December 2012
and a significant portion of these products will be manufactured at the Group`s
manufacturing facility in Durban (Cipla Medpro Manufacturing) which will assist
in generating significant volumes for the plant.
The Group has been awarded the full tender volumes on the following products:
- Emtricitabine 200mg / Tenofovir 300mg Tablets (this combination, part of
the Department of Health (DOH) first choice, first-line treatment regimen
in adults, is the second largest product by value, including all categories
of medicines, in the private sector);
- Lamivudine 300mg Tablets (forms part of the DOH first choice, first-line
treatment regimen in adults); and
- Zidovudine 100mg Tablets
In addition, the Group has secured portions of the following products:
- Abacavir 20mg/ml Solution (forms part of the DOH first choice, first-line
treatment regimen in children);
- Efavirenz 600mg Tablets (forms part of the DOH first choice, first-line
treatment regimen in adults);
- Lamivudine 150mg / Zidovudine 300mg Tablets;
- Lamivudine Scored Tablets 150mg;
- Nevirapine 200mg Tablets; and
- Nevirapine 50mg/5ml Suspension.
The total value of this allocation of products, based on current DOH estimates,
is R633 million (including VAT), with opportunities for further gains.
Cipla Medpro CEO, Jerome Smith, responded to the award of the ARVs by saying:
"These results are extremely pleasing for the Group, and will further assist us
in achieving our vision of providing affordable healthcare to all."
14 December 2010
Durban
Sponsor
Nedbank Capital
Date: 14/12/2010 15:26:01 Produced by the JSE SENS Department.
The SENS service is an information dissemination service administered by the
JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or
implicitly, represent, warrant or in any way guarantee the truth, accuracy or
completeness of the information published on SENS. The JSE, their officers,
employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature,
howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
